XML 49 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 08, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Trading Symbol JANX    
Security12b Title Common Stock, $0.001 par value per share    
Security Exchange Name NASDAQ    
Entity Registrant Name Janux Therapeutics, Inc.    
Entity Central Index Key 0001817713    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period true    
ICFR Auditor Attestation Flag false    
Entity Public Float     $ 204.8
Entity Common Stock, Shares Outstanding   41,833,315  
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Shell Company false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-40475    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 82-2289112    
Entity Address, Address Line One 10955 Vista Sorrento Parkway, Suite 200    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92130    
City Area Code 858    
Local Phone Number 751-4493    
Documents Incorporated by Reference

Portions of the Registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant’s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K.

    
Auditor Name Ernst & Young LLP    
Auditor Firm ID 42    
Auditor Location San Diego, California